A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.
Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.
Ludwig Cancer Research extends its warmest congratulations to Don Cleveland, who has been a Member of the Ludwig Institute for Cancer Research since 1995 and today was awarded the prestigious Breakthrough Prize.
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.
Ludwig Cancer Research has released the scope of its participation at this year’s Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, November 16-19.
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy.
Ludwig Cancer Research has released the scope of its participation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland, November 8-12.
A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response.
Ludwig researchers show how a method that physically expands tissues can improve early breast cancer diagnostics and extend the capabilities of ordinary pathology labs
Ludwig Cancer Research released today the full scope of Ludwig’s participation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.
The loss of the tumor suppressor gene PTEN has been linked to tumor growth and chemotherapy resistance in the almost invariably lethal brain cancer glioblastoma multiforme (GBM). Now, Ludwig researchers have shown that one way to override the growth-promoting effects of PTEN deletion is, surprisingly, to inhibit a separate tumor suppressor gene.
Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.
Ludwig researchers have shown that triple-negative breast cancer cells ramp up production of a key component of DNA in response to chemotherapy and that targeting this pathway could undermine their resistance to such therapies.
Ludwig researchers discover that circular DNA, once thought to be rare in tumor cells, is actually very common and seems to play a fundamental role in tumor evolution
Findings uncover an ancient mechanism that makes cancer cells invasive, explains melanoma’s resistance to therapy and opens the door to development of novel cancer therapies
It is with great pleasure that the Ludwig Institute for Cancer Research announces the appointment of Chi Van Dang as its Scientific Director.
The Ludwig Institute for Cancer Research extends a warm welcome to Barbara S. Jones, the newest member of our Board of Directors.
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body’s immune system from attacking tumors.
A Ludwig Cancer Research study published in the current issue of Scientific Reports describes a new method and risk model to assess how aggressive a bladder cancer is likely to be. “If confirmed in larger studies, our findings could help physicians get a better handle on how a patient’s bladder cancer is likely to progress and allow them to personalize treatment on the basis of that knowledge,” said Ralph Weichselbaum, director of the Ludwig Center at Chicago University, who led the study.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right